Symbols

HRMY

Harmony·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HRMY

Harmony Biosciences Holdings, Inc.

A pharmaceutical company focused on therapies for rare neurological diseases

Industry

Pharmaceutical

Established Date

07/25/2017

Listing Date

08/19/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

268

Fiscal Year Ends

12-31

Website

www.harmonybiosciences.com

Security Type

Common stock

Office address

630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462

Business

Introduction

Harmony Biosciences Holdings, Inc., founded on July 25, 2017, is a commercial-stage pharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with rare neurological diseases with unmet medical needs. The company's product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action, or MOA, specifically designed to enhance histamine signaling in the brain by binding to H3 receptors.

Earnings Call

Q2/2025

Estimate EPS1.04

Actual EPS0.92

Estimate Revenue204.12M

Actual Revenue200.50M

Harmony Biosciences' Q2 2025: Unraveling Contradictions in ZYN002 and WAKIX Strategies

Aug 05,2025 04:14·
Earnings Decrypt

Company Financials

EPS

HRMY has released its 2025 Q3 earnings. EPS was reported at 1.08, versus the expected 0.86, beating expectations. The chart below visualizes how HRMY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HRMY has released its 2025 Q3 earnings report, with revenue of 239.46M, reflecting a YoY change of 28.71%, and net profit of 50.87M, showing a YoY change of 10.35%. The Sankey diagram below clearly presents HRMY's revenue sources and cost distribution.